India has emerged as a significant hub for early-stage drug development, making preclinical studies in India an increasingly relevant option for sponsors seeking skilled scientific expertise, cost-effective infrastructure, a modern regulatory framework, and growing GLP-certified capabilities. Preclinical studies in India are critical for the success or failure of drug development, with factors like study design, regulatory compliance, and facility standards impacting timelines and budgets. The article outlines the components of preclinical studies, the regulatory environment in India, and the role of an experienced CRO partner like CurexBio in assisting sponsors throughout the process.

 

Preclinical studies involve laboratory and animal investigations conducted prior to human testing of new drugs, biologics, vaccines, or medical products. These studies serve to demonstrate a candidate’s biologically plausible effects and to establish a safety profile that supports the initial human dosing and trial design. 

    • Does the molecule engage its target and produce the intended pharmacological effect?
    • How is it absorbed, distributed, metabolized, and excreted?
    • At what doses does it cause toxicity, which organs are affected, and is the toxicity reversible?
    • What starting dose and dose range are reasonable for a Phase I trial?

 

Before formal regulatory studies, discovery teams identify the biological target, screen compounds, and choose lead candidates based on potency, selectivity, and drug-like properties. These exploratory, non-GLP studies are critical for ensuring smoother regulatory processes later, supported by thorough documentation.

 

  • In vitro and in vivo pharmacology (efficacy)

Primary pharmacodynamic studies utilize cell-based assays and animal disease models for proof of concept, while secondary pharmacology examines off-target activity to highlight potential safety issues.

 

  • ADME and pharmacokinetics

ADME (absorption, distribution, metabolism, excretion) and pharmacokinetics (PK) studies assess how the body processes a compound. These studies encompass in vitro metabolic stability, permeability assays, plasma protein binding, CYP enzyme inhibition and induction, as well as in vivo PK analyses in both rodent and non-rodent species. Toxicokinetics, which connects exposure levels to toxic effects, is integrated into the toxicology studies.

 

  • Safety pharmacology

Core battery studies evaluate the impact of a candidate on vital organ systems, including cardiovascular (with a focus on hERG and QT liability), central nervous system, and respiratory function, adhering to ICH S7A and S7B guidelines.

 

  • General toxicology

This component is the largest and most resource-intensive, comprising single-dose toxicity studies, repeat-dose toxicity studies in both rodent and non-rodent species aligned with clinical trial duration, and dose range-finding studies. The design and species selection are guided by ICH M3(R2), ICH S6(R1), and ICH S9 for small molecules, biotechnology products, and anticancer pharmaceuticals, respectively.

 

  • Genotoxicity

A standard battery comprises a bacterial reverse mutation (Ames) test, an in vitro chromosomal damage assay, and an in vivo micronucleus test, as per ICH S2(R1).

 

 

  • Reproductive and developmental toxicity, and other studies

Sponsors may require various studies such as fertility, embryo-fetal development, local tolerance, immunotoxicity, phototoxicity, or carcinogenicity assessments, depending on the product and patient population. The timing of these studies in relation to clinical phases is outlined in ICH guidance.

 

 

  • Formulation and CMC support

Toxicology studies require well-characterized test materials reflective of the clinical batch, along with essential dose formulation analysis, stability, and homogeneity checks for reliable results.

 

 

  • Integration into an IND-enabling package

All study reports are compiled into a nonclinical overview and summaries, which are essential for the regulatory submission of first-in-human trials.

 

Regulatory Requirements for Preclinical Studies in India

Preclinical studies in India involve aspects of drug regulation, animal welfare law, and quality standards, necessitating sponsors to be well-informed about these areas.

  1. The New Drugs and Clinical Trials Rules, 2019 (NDCT Rules), overseen by the Central Drugs Standard Control Organization (CDSCO) and the Drugs Controller General of India (DCGI), replaced Schedule Y. These rules outline the approval requirements for new drugs and clinical trials, detailing non-clinical data such as animal toxicology and pharmacology necessary for applications. They establish review timelines, with shorter reviews for drugs discovered in India and longer ones for those developed abroad. Applications must be submitted via the SUGAM portal. 
  2. Animal experimentation in India is governed by the Prevention of Cruelty to Animals Act, 1960, and related regulations. The Committee for the Control and Supervision of Experiments on Animals (CPCSEA) oversees facility registration and inspections. Each registered facility must have an Institutional Animal Ethics Committee (IAEC) to review and approve protocols prior to commencing any work. Sponsors should ensure that their Contract Research Organization (CRO) has valid CPCSEA registration and that all protocols are approved by the IAEC. 
  3. Good Laboratory Practice (GLP) ensures that regulatory safety studies yield reliable, traceable, and reconstructable data. In India, compliance is overseen by the National GLP Compliance Monitoring Authority (NGCMA) under the Department of Science and Technology. Adherence to the OECD Mutual Acceptance of Data system allows data from NGCMA-certified facilities to be accepted by regulators in other OECD countries, preventing the need for redundant studies. 
  4. OECD guidelines specify standard toxicity and genotoxicity assays, whereas ICH guidelines outline requirements for clinical development stages. Compliance with both ensures effective submissions for Indian and international markets. 
  5. Recent amendments to the NDCT Rules allow for non-animal testing methods, like in vitro and in silico approaches, in certain situations. Sponsors are encouraged to consult with regulators early in the process and ensure compliance with current requirements, which may change. Verifying regulations with CDSCO and relevant authorities is essential before finalizing development plans. 

 

Common Pitfalls in Preclinical Programs

When conducting preclinical studies in India, choosing inappropriate species, conducting underpowered studies, failing to comply with GLP and CPCSEA regulations, inadequate test article characterization, and delaying regulatory planning can compromise data quality and regulatory submissions.

 

How a CRO Supports Preclinical Development

Early-stage sponsors, including biotech startups and pharmaceutical companies, may lack the in-house capabilities needed to manage preclinical studies in India, making specialized Contract Research Organizations (CROs) valuable partners throughout the development process. These CROs offer expertise in several key areas: study design and strategy (creating regulatory-compliant preclinical plans), execution of studies (conducting pharmacology, toxicology, and other studies), bioanalysis (method development, sample analysis), regulatory writing (preparing protocols and reports), and project management (coordinating studies and communication).

 

CurexBio supports sponsors through the preclinical process by providing regulatory-aligned planning, comprehensive study portfolio assistance, compliance-focused execution, clear reporting, and a collaborative approach. We ensure study designs meet NDCT, ICH, and OECD standards, assist with all necessary studies for IND packages, adhere to GLP and local regulations, produce organized submission-ready reports, and maintain open communication throughout the program. 

 

If you are planning an IND-enabling program and would like to discuss your molecule, timelines, or regulatory strategy, get in touch with the CurexBio team to explore how we can support your next milestone.

 

Read our previous blog: https://curexbio.com/pk-pd-analysis-in-france-for-drug-development/